APTX Aptinyx Inc.

4.44
-0.16  -3%
Previous Close 4.6
Open 5
Price To Book 1.32
Market Cap 149,539,045
Shares 33,679,965
Volume 1,373,849
Short Ratio
Av. Daily Volume 259,778
Stock charts supplied by TradingView

NewsSee all news

  1. Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option

    EVANSTON, Ill., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,

  2. Aptinyx Announces Pricing of Public Offering of Common Stock

    EVANSTON, Ill., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,

  3. Aptinyx Announces Proposed Public Offering of Common Stock

    EVANSTON, Ill., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,

  4. Aptinyx to Present at 38th Annual J.P. Morgan Healthcare Conference

    EVANSTON, Ill., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,

  5. Aptinyx to Present Preclinical Data Exhibiting Effects of NYX-783 in Models of PTSD and Alcohol Use Disorder at the American College of Neuropsychopharmacology's Annual Meeting

    EVANSTON, Ill., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial initiation announced December 5, 2019 with initial data due 2H 2021.
NYX-458
Parkinson’s Disease Cognitive Impairment (healthy volunteers)
Phase 2 trial initiation announced November 12, 2019 with data due 1H 2021.
NYX-2925
Fibromyalgia
Phase 2 data released January 16, 2019 - primary endpoint not met. Additional Phase 2 trial initiation announced November 12, 2019 with data due 4Q 2020 / 1Q 2021.
NYX-2925
Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
Phase 2 data due 2H 2020.
NYX-783
Post-traumatic stress disorder (PTSD)

Latest News

  1. Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option

    EVANSTON, Ill., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,

  2. Aptinyx Announces Pricing of Public Offering of Common Stock

    EVANSTON, Ill., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,

  3. Aptinyx Announces Proposed Public Offering of Common Stock

    EVANSTON, Ill., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,

  4. Aptinyx to Present at 38th Annual J.P. Morgan Healthcare Conference

    EVANSTON, Ill., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,

  5. Aptinyx to Present Preclinical Data Exhibiting Effects of NYX-783 in Models of PTSD and Alcohol Use Disorder at the American College of Neuropsychopharmacology's Annual Meeting

    EVANSTON, Ill., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,

  6. Aptinyx Initiates Phase 2 Study of NYX-458 in Patients with Mild Cognitive Impairment Associated with Parkinson's Disease

    Phase 2 study follows NYX-458 preclinical data demonstrating reversal of cognitive deficits in non-human primate model of Parkinson's disease Fourth Phase 2 study initiated by Aptinyx in 2019 across innovative CNS

  7. Aptinyx to Present at Upcoming Investor Conferences

    EVANSTON, Ill., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,

  8. Aptinyx Reports Third Quarter 2019 Financial Results and Highlights

    Initiated two Phase 2 studies of NYX-2925 in chronic pain conditions On track to have four Phase 2 studies ongoing by year end across pipeline of CNS product candidates Conference call today at 5:00 p.m. EST EVANSTON,

  9. Aptinyx Initiates Two Phase 2 Studies of NYX-2925 in Patients with Chronic Centralized Pain Conditions

    200-patient painful diabetic peripheral neuropathy study and 300-patient fibromyalgia study build on previous compelling data obtained in these indications Top-line efficacy and safety data anticipated in late 2020 or

  10. Aptinyx to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

    EVANSTON, Ill., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,

  11. EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Aptinyx Inc.

    NEW YORK, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky reminds investors that it has commenced an investigation of Aptinyx Inc. ("Aptinyx" or "the Company") (NASDAQ:APTX) concerning possible violations of

  12. Kaskela Law LLC Announces Investigation of Aptinyx Inc. (APTX) on Behalf of Investors

    PHILADELPHIA, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Kaskela Law LLC is investigating Aptinyx Inc. ("Aptinyx" or the "Company") (NASDAQ:APTX) on behalf of the Company's investors.  Aptinyx investors are encouraged to

  13. Aptinyx Announces Results of Phase 2 Fibromyalgia Study of NYX-2925 Have Been Selected for Late-Breaking Presentation at the American College of Rheumatology Annual Meeting

    Study met primary and secondary endpoints – statistically significant effects on neuroimaging biomarkers and patient-reported measures ePoster to be presented at ACR Annual Meeting on Tuesday, November 12

  14. Aptinyx to Present Preclinical Data on Three Clinical-Stage NMDA Receptor Modulators at the 49th Annual Meeting of the Society for Neuroscience

    EVANSTON, Ill., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,

  15. Aptinyx to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    EVANSTON, Ill., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,

  16. Three Recent Preclinical Publications Highlight NMDA Receptor Activation Facilitated by Aptinyx's NYX-2925

    EVANSTON, Ill., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,

  17. INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigati

  18. Former Principal Deputy Commissioner of FDA, Dr. Rachel Sherman, Joins Aptinyx Board of Directors

    EVANSTON, Ill., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders,